Progression-Free Survival Early Assessment is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

Progression-Free Survival Early Assessment is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

Background: Radiology-based outcomes, such as progression-free survival (PFS) and objective response rate (ORR), are used as surrogate endpoints in oncology trials. We aimed to assess the surrogacy relationship of PFS with overall survival (OS) in clinical trials of systemic therapies targeting adva...

Full description

Bibliographic Details
Main Authors: Giuseppe Cabibbo, Ciro Celsa, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Anita Busacca, Domenica Matranga, Massimo Attanasio, Maria Reig, Antonio Craxì, Calogero Cammà
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
hepatocellular carcinoma
immunotherapy
surrogate endpoints
progression-free survival
overall survival
Online Access:https://www.mdpi.com/2072-6694/13/1/90

Internet

https://www.mdpi.com/2072-6694/13/1/90

Similar Items